BioCentury
ARTICLE | Clinical News

FV-100: Phase I data

February 16, 2009 8:00 AM UTC

Pooled data from 64 healthy volunteers in 2 double-blind, placebo-controlled Phase I trials showed that FV-100 was well tolerated with no adverse events. Pharmacokinetic data showed that all doses mai...